Postantifungal effect and effects of sub-MIC concentrations on previously treated Candida sp. influnce of growth phase

Journal of Infection

Volumn 45, Issue 4, 2002, Pages 263-267

  Garcia M T ^a   Llorente, M T ^a   Minguez F ^a   Prieto, J ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; KETOCONAZOLE; PYRROLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; CLINICAL PROTOCOL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; FUNGUS CULTURE; FUNGUS GROWTH; GROWTH CURVE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPECIES; TREATMENT PLANNING; WOUND INFECTION;

EID: 0036873515     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2002.1042     Document Type: Article

References (19)

1. Mínguez F, Chiu ML, Prieto J. Efecto postantifúngico. Rev Esp Quimioterap 1993; 6: 33-35.
2. Mínguez F, García MT, Lima JE, Llorente MT, Prieto J. Postantifungal effect and effects of low concentrations of Amphotericin B and Fluconazole on previously treated Candida albicans. Scand J Infect Dis 1996b; 28: 503-506.
3. Troke PF, Marriot MS, Richardson K, Tarbit MH. In vitro and in vivo activity of azoles. Ann NY Acad Sci 1988; 544: 284-293.
4. National Committee for Clinical Laboratory Standards. Reference method for broth dilution susceptibility testing of yeasts. Proposed standard Document M27-P. National Committee for Clinical Laboratory Standard Villanova P 1992a.
5. Craig WA, Gudmundsson S. The postantibiotic effect. In: Lorian, V. (ed.), Antibiotics in Laboratory Medicine, 3 edn Williams & Wilkins, Baltimore, MD 1991; 403-431.
6. Kikuchi K, Enari T, Minami S, Haruki K, Shibata Y, Hasegawa H, Katahira J, Totsoku K, Shimizu, K. Postantibiotic effects and postantibiotic sub-MIC effects of benzylpenicillin on viridans streptococci isolated from patients with infective endocarditis. J Antimicrob Chemother 1994; 34: 687-696.
7. Turnidge JD, Gudmundsson S, Vogelman B, Craig WA. The postantibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother 1994; 34: 83-92.
8. García MT, Llorente MT, Lima JE, Mínguez F, del Moral F, Prieto J. Activity of voriconazole: postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. Scand J Infect Dis 1999; 31: 501-504.
9. Odenholt I. Studies on the postantibiotic effect and the postantibiotic subMIC effect of meropenem. J Antimicrob Chemother 1993; 31: 881-892.
10. Mínguez F, Lima JE, García MT, Prieto J. Influence of human serum on the postantifungal effect of four antifungal agents on C. albicans. Chemotherapy 1996a; 42: 273-279.
11. Meunier F, Lambert C, Van der Auwera P. In vitro activity of SCH39304 in comparison with amphotericin Band fluconazole. J Antimicrob Chemother 1990; 25: 227-236.
12. Walsh TJ, Pizzo PA. Nosocomial fungal infections: a classification for hospital-acquired infections and mycoses arising from endogenous flora or reactivation. Annu Rev Microbiol 1988; 42: 517-545.
13. Walsh TJ, Pizzo P. Treatment of systemical fungal infections: recent progress and current problems. Eur J Clin Microbiol 1988; 7: 460-475
14. Swoboda RK, Bertram G, Delbruck S, Ernst JF, Gow NA, Gooday GW, Brown AJ. Fluctuations in glycolytic mRNA levels during morphogenesis in Candida albicans reflect underlying changes in growth and are not a response to cellular dimorphism. Mol Microbiol 1994; 13: 663-672.
15. Buchan AD, Gow NA. Rates of germ tube formation from growing and non growing yeast cells of Candida albicans. FEMS Microbiol Lett 1991; 65(1): 15-18.
16. King RD, Lee JC, Morris AL. Adherence of Candida albicans and other Candida species to mucosal epithelial cells. Infect Immun 1980; 27: 667-674.
17. Lee JC, King RD. Characterization of Candida albicans adherence to human vaginal epithelial cells in vitro. Infect Immun 1983; 41: 1024-1030.
18. Beggs WH. Growth phase in relation to ketoconazole and miconazole susceptibilities of Candida albicans. Antimicrob Agents Chemother 1984; 25: 316-318.
19. Cope JE. The interaction of 3H miconazole with Candida albicans. Sabouraudia 1980; 18: 211-228.